Business Context and Reporting Period
Company: OrthoPediatrics Corp. (Nasdaq: KIDS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: OrthoPediatrics is a global medical device company focused exclusively on pediatric orthopedic conditions, offering trauma and deformity correction, scoliosis, and sports medicine products. The company utilizes a contract manufacturing model for implants and operates over 50 orthotic and prosthetic (O&P) clinics in the U.S.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
|---|---|---|
| Net Revenue | $70,508 | $129,869 |
| Gross Profit | $52,366 | $95,756 |
| Gross Margin | 74.3% | 73.7% |
| Operating Loss | $(4,068) | $(12,402) |
| Net Loss | $(7,163) | $(17,850) |
| Diluted Net Loss Per Share | $(0.30) | $(0.75) |
| Cash and Short-Term Investments | $45,879 (as of June 30, 2026) | N/A |
| Total Debt (Gross) | $105,751 (as of June 30, 2026) | N/A |
Note: Cash and Short-Term Investments calculated as Cash ($17,001) + Restricted Cash ($2,054) + Short-term Investments ($28,878).
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 15% ($9.4M) for the quarter and 14% ($16.4M) for the six months compared to the same periods in 2025. Growth was driven by strong performance in Trauma and Deformity products (up 26% QoQ) and O&P Specialty Bracing.
- Product Mix Shift: While Trauma and Deformity sales surged, Scoliosis sales decreased 9% ($1.6M) for the quarter, attributed to lower revenue from 7D Technology and reduced set sales to international distributors.
- Expense Reduction: Restructuring expenses dropped significantly to $1 for the current periods compared to $2.97M and $3.01M in the prior year, following the completion of the 2024 global restructuring plan.
- Operating Efficiency: Gross margin improved to 74% for both the quarter and six months ended June 30, 2026, up from 72% in the prior year periods.
- Cash Flow Improvement: Net cash used in operating activities decreased to $2.4M for the six months ended June 30, 2026, a significant improvement from $14.6M used in the prior year period, driven by lower inventory purchases and stronger accounts receivable collections.
Guidance, Outlook, and Risks
Management Commentary: Management anticipates continued losses in the near term as the company invests in expanding its product portfolio and consigned inventory to support market expansion. The company remains compliant with all debt covenants.
Liquidity and Capital Resources: As of June 30, 2026, the company held approximately $47.9M in cash, cash equivalents, restricted cash, and short-term investments. The company has a $100M financing facility with Braidwell LP (comprising a $50M term loan and $50M convertible notes). A new $20M delayed draw term loan facility was added via amendment in March 2026, available until June 30, 2027.
Risks and Contingencies:
- Legal Proceedings: An arbitration regarding software ownership (IMED Surgical) was dismissed with prejudice against the plaintiff in April 2026. No other material legal proceedings are currently pending.
- Acquisition Integration: The company continues to integrate multiple acquisitions (e.g., MedTech, Boston O&P, LOC, Brazil distributor), with some purchase price allocations still preliminary.
- Market Risks: Exposure to interest rate fluctuations on variable-rate debt and foreign currency exchange rate risks, particularly regarding the Euro and British Pound.
Investor Verification Checklist
- Debt Covenants: Verify continued compliance with the Braidwell Term Loan covenants, specifically the requirement to maintain unrestricted cash equal to at least 25% of outstanding principal.
- Acquisition Earnouts: Monitor performance metrics for recent acquisitions (LOC, Brazil distributor, Boston O&P) that trigger contingent earnout payments.
- Inventory Levels: Review the $137.6M inventory balance, noting that approximately 60% is held on consignment, which impacts working capital and revenue recognition timing.
- Convertible Note Conversion: Assess the risk of dilution from the $50M convertible notes (conversion price ~$40.98) if stock price thresholds are met.
- Restructuring Completion: Confirm that the nominal restructuring expenses in 2026 indicate the full execution of the 2024 cost-reduction plan.